financetom
Business
financetom
/
Business
/
Healthpeak Properties raises annual FFO estimate on steady demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Healthpeak Properties raises annual FFO estimate on steady demand
Oct 26, 2024 12:20 AM

Oct 24 (Reuters) - Healthpeak Properties ( DOC ) raised

the lower-end of its annual funds from operations (FFO) forecast

on Thursday, banking on steady demand for its medical office and

life science properties.

The U.S. healthcare-centric company now expects its 2024

adjusted FFO, a key performance measure for real estate

investment trusts, to be in the range of $1.79 to $1.81 per

share, compared to its previous estimate of $1.77 to $1.81 per

share.

Analysts, on average, were expecting adjusted FFO of $1.79

per share, as per data compiled by LSEG.

Demand for the outpatient & life science sites owned by the

company has benefited from a rise in patient visits, creating a

favorable leasing environment.

The Denver, Colorado-based firm posted adjusted FFO of 45

cents per share in the third quarter, largely in line with

analysts' estimate of 44 cents per share.

The company reported total revenue of $700.40 million for

the quarter ended Sept. 30, beating estimates of $680.25

million.

The REIT owns medical office and life science assets, as

well as senior housing, hospital and post-acute care assets.

Healthpeak's lab portfolio is mainly concentrated in San

Francisco and San Diego, California, as well as in Boston,

Massachusetts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck's Verquvo Fails to Meet Primary Endpoint in Phase 3 Victor Trial
Merck's Verquvo Fails to Meet Primary Endpoint in Phase 3 Victor Trial
Sep 2, 2025
07:00 AM EDT, 09/02/2025 (MT Newswires) -- Merck ( MRK ) said Saturday that its phase 3 Victor trial evaluating Verquvo, or vericiguat, in adult patients with stable chronic heart failure and reduced ejection fraction did not reach statistical significance for its primary endpoint of combined time to first cardiovascular death or heart failure hospitalization. The trial compared Verquvo against...
Blackstone-backed Legence targets nearly $3 billion valuation in US IPO
Blackstone-backed Legence targets nearly $3 billion valuation in US IPO
Sep 2, 2025
Sept 2 (Reuters) - Engineering and maintenance services provider Legence is targeting a valuation of up to $2.95 billion in its U.S. initial public offering, it said on Tuesday, as the new listings market kicks back into action after the seasonal summer slowdown. San Jose, California-based Legence, a Blackstone portfolio company, is seeking up to $754 million by offering 26...
Bermuda-based Signet Jewelers Q2 revenue beats estimates, raises FY26 guidance
Bermuda-based Signet Jewelers Q2 revenue beats estimates, raises FY26 guidance
Sep 2, 2025
Overview * Signet fiscal Q2 revenue rises, beating analyst expectations, per LSEG data * Adjusted EPS for fiscal Q2 beats consensus, per LSEG data * Company raises FY26 guidance, indicating confidence in strategic initiatives Outlook * Signet raises FY26 sales guidance to $6.67-$6.82 bln * Company expects Q3 sales between $1.34 bln and $1.38 bln * Signet sees FY26 adjusted...
Dow sells additional stake in infrastructure venture for $540 million
Dow sells additional stake in infrastructure venture for $540 million
Sep 2, 2025
Sept 2 (Reuters) - Dow said on Tuesday it has sold an additional stake in its infrastructure venture to its partner Macquarie Asset Management for $540 million as the chemical maker looks to focus more on its core business. The deal raises Macquarie's stake in the venture, Diamond Infrastructure Solutions, to 49%, and brings Dow's total proceeds from the transaction...
Copyright 2023-2026 - www.financetom.com All Rights Reserved